



Curie-Cancer and Sanofi cooperate in research on ovarian cancer

- Preclinical program of translational research to identify new target proteins -

Paris, France – June 19, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, announce today the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.

The aim of the collaboration between Sanofi and Curie-Cancer is to revisit the basic biology of this type of cancer through a translational research approach. The Institut Curie has a large collection of cryopreserved tumor samples that are well characterized clinically, histologically and biologically. These can be analyzed to identify biological targets relevant to the effective treatment of certain types of cancer. Through this collaboration, Sanofi and Curie-Cancer expect to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed.

"We hope this type of long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease. It will combine the accumulated knowledge on ovarian cancer gathered over many years by oncologists and biologists at the Institut Curie with the expertise of researchers from Sanofi's research and product development teams," said Dr. Debasish Roychowdhury, Senior Vice President and Head of Sanofi Oncology. *"Established under the Aviesan¹ partnership, this research agreement is a good example of translational research involving French scientific excellence."*

"It is hard currently to tackle ovarian cancer, and there are very few drugs available. To potentially provide our patients with additional therapeutic solutions, we are very happy to collaborate with Sanofi, whose expertise in the selection of therapeutic targets is complementary to the know-how and technology platforms developed at the Institut Curie" said Damien Salauze, Director of Curie-Cancer.

Using technology platforms developed by the Institut Curie by Xavier Sastre-Garau and Sergio Roman-Roman groups, this program will make it possible to sequence molecules expressed by the tumor genome, compare the sequences of those obtained with non-tumor tissues from the same patients, and then clarify and validate the nature of the molecular alterations that are identified. Sanofi's expertise in the selection of therapeutic targets will then guide an assessment of the tumor's ability to be inhibited or stimulated by drugs.

Ovarian cancer is still difficult to treat, despite recent advances. The main risk factor is advancing age, as well as a known hereditary factor in 5-10% of cases. They are most often diagnosed late. The current therapeutic strategy of combining surgery and chemotherapy is effective, but relapses are frequent and the condition gradually becomes resistant to medical treatment.

About Curie-Cancer

¹Alliance Nationale pour les Science de la Vie et de la Santé (French National Alliance for Life Sciences and Health)

Curie-Cancer is the body responsible for developing Institut Curie's industry partnership activities. It oversees the institute's existing industry partnerships as well as areas of high potential interest to industry partners. Institut Curie's 1,200 researchers provide the high level of expertise in oncology required to collaborate with industry partners in creating and subsequently developing cancer therapies.

Curie-Cancer management has extensive industry experience and can call upon a vast pool of scientists involved in basic and clinical research. In 2011, Curie-Cancer was awarded the "Institut Carnot" label by the French government, which recognizes excellence and involvement in research partnerships.

About Institut Curie

Institut Curie is a private foundation founded in 1909 by Marie Curie, the first woman Nobel prize-winner and the first double Nobel prize-winner. It is the leading comprehensive cancer center (combining research and patient care) in Europe. Institut Curie's research center and hospital employ some 3,200 scientists, physicians, nurses, technicians and administrative staff. The institute's current objectives include increasing the proportion of research programs carried out in partnership with industry so that research results can lead to faster availability of products and services for the benefit of patients. For more information, go to: <http://www.curie.fr/en>

About Sanofi Oncology

Sanofi Oncology is a global division of Sanofi based in Cambridge, Massachusetts and Vitry, France. At Sanofi Oncology, the patient is our inspiration. We are dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Through our global organization of talented and passionate employees, we are building a renewed and diversified portfolio, driven by the principles of innovation, personalization and patient access to medicines. We believe that delivering innovative treatment solutions requires collaboration with external experts, which is why we partner our own internal expertise with the best experts in scientific discovery and clinical research around the world.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December

31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Sanofi

Media Relations

Frédéric Lemonde-San

Tél. : + (33) 1 53 77 91 55

frederic.lemonde@sanofi.com

Lauren Musto

Oncology Division Communications

Tel: 1 (617) 768-1993; Mobile 1(781) 572-1147

lauren.musto@sanofi.com

Curie-Cancer

Damien Salauze

damien.salauze@curie.fr

Investor Relations

Sébastien Martel

Tél. : + (33) 1 53 77 45 45

ir@sanofi.com

Médias et analystes

Andrew Lloyd & Associates

Juliette dos Santos / Céline Gonzalez

Tél. : +(33) 1 56 54 07 07

juliette@ala.com / celine@ala.com